Brian Rini, MD
Hematology & Oncology · Nashville, TNNPI 1144261231
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Merck at 47.6% of the total. Reporting peaked in 2019 at $146,068 and has fallen 60.7% since, to $57,333 in 2025. Among hematology & oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $1873.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$286K
- Eisai Inc.$60K
- Pfizer$52K
- E.r. Squibb & Sons, L.L.C.$37K
- GSK$25K
- USWM, LLC$15K
- plus $127K from 29 others
Across 260 payments — averaging $28,822 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3M
- Pfizer$2.3M
- AstraZeneca$915K
- Daiichi Sankyo Inc.$400K
- Genentech, Inc.$369K
- Novartis$192K
- plus $377K from 6 others
What the payments were for
- Consulting fees$306,42251%
- Speaking & faculty fees$210,46835%
- Travel & lodging$75,40013%
- Food & beverage$6,6071%
- Education$2,0700%
- Entertainment$3910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 146 | $286,054 |
| Eisai Inc. | 29 | $59,822 |
| Pfizer(2 entities) | 30 | $51,629 |
| E.r. Squibb & Sons, L.L.C. | 27 | $36,628 |
| GSK | 3 | $25,075 |
| USWM, LLC | 2 | $15,000 |
| Eisai CO., LTD. | 3 | $14,275 |
| Astrazeneca UK Limited | 8 | $12,807 |
| EUSA Pharma (US) LLC | 3 | $11,850 |
| Alkermes, Inc. | 3 | $10,700 |
| Hoffmann-la Roche Limited | 2 | $8,396 |
| Eli Lilly | 1 | $8,313 |
| Janssen Research & Development, LLC | 1 | $6,750 |
| Incyte Corporation | 1 | $6,700 |
| F. Hoffmann-la Roche AG | 7 | $6,211 |
| Genentech, Inc. | 3 | $5,698 |
| AVEO Pharmaceuticals, Inc. | 13 | $5,554 |
| Whitehall International Inc | 3 | $4,929 |
| Novartis | 2 | $4,078 |
| Shionogi Inc | 1 | $4,000 |
| Genmab U.S., Inc. | 2 | $3,593 |
| Dr.reddy's Laboratories,inc. | 2 | $3,500 |
| AstraZeneca | 4 | $3,138 |
| Roche Products Limited | 5 | $2,692 |
| Johnson & Johnson | 1 | $1,388 |
| Tempus AI, Inc | 3 | $1,007 |
| Janssen Scientific Affairs, LLC | 2 | $291 |
| Regeneron Healthcare Solutions, Inc. | 2 | $278 |
| Gilead | 4 | $266 |
| Exelixis Inc. | 1 | $172 |
| Bristol Myers Squibb | 1 | $170 |
| Photocure Inc | 1 | $163 |
| Bayer | 1 | $123 |
| Telix Pharmaceuticals | 3 | $91 |
| Myovant Sciences Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$601,357 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 86 | $1,826,676 |
| WeliregBelzutifan | 47 | $1,286,457 |
| XtandiEnzalutamide | 58 | $803,355 |
| FotivdaTivozanib Hcl | 28 | $771,005 |
| LenvimaLenvatinib Mesylate | 24 | $557,243 |
| InlytaAxitinib | 23 | $383,886 |
| Abiraterone Acetate | 128 | $328,295 |
| OrgovyxRelugolix | 101 | $256,052 |
| NubeqaDarolutamide | 21 | $251,149 |
| EliquisApixaban | 17 | $11,627 |
| Everolimus | 11 | $10,964 |
| Prednisone | 105 | $494 |
| Oxycodone Hcl | 21 | $277 |
| Levothyroxine Sodium | 21 | $152 |
| Tamsulosin Hcl | 16 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $172 | $1,826,67686 claims |
| MerckWelireg | $286,054 | $1,286,45747 claims |
| Eisai Inc.Lenvima | $59,822 | $557,24324 claims |
| PfizerInlyta, Eliquis | $51,629 | $395,51340 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $291 | $328,295128 claims |
| BayerNubeqa | $123 | $251,14921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
- Jack ErterNashville$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.